恩威医药
(301331)
| 流通市值：23.54亿 | | | 总市值：23.61亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 565,324,690.15 | 374,578,793.61 | 175,328,944.36 | 900,771,087.12 |
| 营业收入 | 565,324,690.15 | 374,578,793.61 | 175,328,944.36 | 900,771,087.12 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 545,811,310.69 | 363,426,013.64 | 163,762,300.69 | 842,272,742.13 |
| 营业成本 | 284,041,071.34 | 182,855,635.04 | 77,688,967 | 454,778,491.76 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 6,869,277.42 | 4,298,743.62 | 1,891,907.28 | 11,272,037.86 |
| 销售费用 | 201,326,606.99 | 139,363,679.76 | 65,998,687.9 | 301,142,873.72 |
| 管理费用 | 49,692,466.6 | 33,983,710.08 | 16,727,582.78 | 69,943,838.4 |
| 研发费用 | 3,549,697.43 | 2,377,732.03 | 1,114,464.19 | 5,522,560.06 |
| 财务费用 | 332,190.91 | 546,513.11 | 340,691.54 | -387,059.67 |
| 其中:利息费用 | 1,725,016.65 | 1,080,134.61 | 578,125 | 2,561,203.19 |
| 其中:利息收入 | 1,548,817.71 | 654,151.13 | 300,085.69 | 3,143,438.4 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -4,315,689.39 |
| 加:投资收益 | 2,598,766.41 | 1,930,455.38 | 1,391,909.91 | 5,200,000.98 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | -125,576.42 | -125,576.42 | - | -138,008.49 |
| 资产减值损失(新) | -155,136.87 | 98,850.92 | -371,726.67 | 1,978,345.29 |
| 信用减值损失(新) | 70,684.48 | 590,504.25 | 565,933.87 | -1,884,835.73 |
| 其他收益 | 2,583,537.17 | 1,700,195.15 | 937,390.08 | 3,020,886.05 |
| 四、营业利润 | 24,485,654.23 | 15,347,209.25 | 14,090,150.86 | 62,359,043.7 |
| 加:营业外收入 | 3,105,941.34 | 2,816,912.7 | 1.02 | 2,129,004.62 |
| 减:营业外支出 | 221,406.57 | 209,581.97 | 207,248.45 | 324,292.27 |
| 五、利润总额 | 27,370,189 | 17,954,539.98 | 13,882,903.43 | 64,163,756.05 |
| 减:所得税费用 | 4,946,358.94 | 1,931,666.1 | 1,378,171.11 | 12,218,819.4 |
| 六、净利润 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| 终止经营净利润 | - | - | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| 少数股东损益 | - | - | - | 0 |
| 扣除非经常损益后的净利润 | 15,655,214.71 | 10,802,337.65 | 10,695,869.85 | 46,522,944.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.22 | 0.16 | 0.12 | 0.5 |
| (二)稀释每股收益 | 0.22 | 0.16 | 0.12 | 0.5 |
| 八、其他综合收益 | - | - | - | 0 |
| 归属于母公司股东的其他综合收益 | - | - | - | 0 |
| 九、综合收益总额 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| 归属于母公司股东的综合收益总额 | 22,423,830.06 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 |
| 归属于少数股东的综合收益总额 | - | - | - | 0 |
| 公告日期 | 2026-10-26 | 2026-08-27 | 2026-04-27 | 2026-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |